Axelia Oncology is a biopharmaceutical company aiming to transform the treatment of checkpoint insensitive cancers through the activation of TLR2/6 engagement of the innate immune response...
Axelia Oncology is developing AXA-042, a potent selective, systemically delivered, TLR2/6 agonist for solid tumour indications.